Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome
Structural and numerical alterations of chromosome 21 are extremely common in hematological malignancies. While the functional impact of chimeric transcripts from fused chromosome 21 genes such as TEL-AML1, AML1-ETO, or FUS-ERG have been extensively studied, the role of gain of chromosome 21 remains largely unknown.
Keywords:
Animals; Child; Chromosome Aberrations; Chromosomes, Human, Pair 21; Down Syndrome/complications/drug therapy; Epigenesis, Genetic; Humans; Janus Kinase 2/genetics
Abstract:
Structural and numerical alterations of chromosome 21 are extremely common in hematological malignancies. While the functional impact of chimeric transcripts from fused chromosome 21 genes such as TEL-AML1, AML1-ETO, or FUS-ERG have been extensively studied, the role of gain of chromosome 21 remains largely unknown.